Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €46.27 EUR
Change Today -0.09 / -0.19%
Volume 1.1M
DSM On Other Exchanges
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv (DSM) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/26/15 - €55.37
52 Week Low
09/29/15 - €38.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KONINKLIJKE DSM NV (DSM)

Related News

No related news articles were found.

koninklijke dsm nv (DSM) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv (DSM) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates through Nutrition, Performance Materials, Polymer Intermediates, and Innovation Center segments. It manufactures food enzymes, cultures, yeast extracts, savory ingredients, and other specialty ingredients for the food and beverage industries; and nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, minerals, and nutritional lipids, as well as active and performance ingredients for the feed, food, pharmaceutical, and personal care industries. The company also offers Dyneema, a strong fiber; specialty plastics that are used in components for the electrical and electronic, automotive, flexible food packaging, and consumer goods industries; and resins solutions for paints and coatings, composite materials, and fiber optic coatings. In addition, it produces fiber intermediates, such as caprolactam, which is used as raw material for polyamide 6; acrylonitrile that is used as a raw material for acrylic fibers, plastics, rubber, water treatment chemicals, and various specialty products; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, diaminobutane, pyrrolidine, and acetonitrile. Further, the company provides bio-based chemicals and materials; KhepriCoat, which enables glass to transmit light for use in solar energy and lighting industries, as well as in horticultural and agricultural greenhouses; and develops and produces materials, as well as components, sub-assemblies, and medical devices for its customers. Koninklijke DSM N.V. was founded in 1902 and is headquartered in Heerlen, the Netherlands.

20,926 Employees
Last Reported Date: 08/4/15
Founded in 1902

koninklijke dsm nv (DSM) Top Compensated Officers

Chairman of the Managing Board and Chief Exec...
Total Annual Compensation: €1.2M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €630.0K
Member of the Managing Board
Total Annual Compensation: €724.0K
Member of the Managing Board
Total Annual Compensation: €724.0K
Compensation as of Fiscal Year 2014.

koninklijke dsm nv (DSM) Key Developments

EnvisionTEC Teams with Somos® to Develop High-Performance Materials

EnvisionTEC announce its collaboration with DSM’s product brand Somos. The partnership will allow both companies to advance their technologies and develop new applications.

DSM to Axe over 900 Jobs by 2017

DSM announced that it will slash 900 to 1,100 jobs by the end of 2017 in a cost-cutting exercise, amounting to about half of its Netherlands-based staff. The restructuring will apply to finance, human resources, legal, IT, corporate communications and regional centres among others. DSM expected to save between €125 million ($143 million) to €150 million annually from the end of 2017 onwards.

Koninklijke Dsm N.V. Reports Earnings Results for the Second Quarter of 2015; Provides Earnings Guidance for the Year 2015

Koninklijke DSM N.V. reported earnings results for the second quarter of 2015. For the quarter, the company reported sales were €1,965 million, a 12% increase versus second quarter of 2014, due to 3% higher volumes, 2% lower prices, 10% positive foreign exchange effects and 1% acquisition effects. DSM delivered a 6% higher EBITDA of €279 million compared to €264 million in second quarter of 2014. Financial income and expense in second quarter of 2015 amounted to €35 million compared to €32 million in second quarter of 2014 which was mainly due to higher interest expenses as a result of a higher debt. The effective tax rate in second quarter of 2015 remained 18%, in line with the full year 2014. Net profit from continuing operations, before exceptional items in second quarter of 2015 amounted to €110 million compared to €108 million in second quarter of 2014. Net earnings per ordinary share (continuing operations, before exceptional items) amounted to €0.63 in second quarter of 2015 compared to €0.62 in second quarter of 2014. Cash provided by operating activities from continuing operations in second quarter of 2015 was €103 million compared to €124 million for the same period a year ago. Cash used for capital expenditure net of customer funding (continuing operations) amounted to €107 million in second quarter of 2015 compared to €90 million in second quarter of 2014. Net debt decreased by €69 million compared to first quarter of 2015, reflecting the cash flow contribution and a positive development in mark-to-market value of financial derivatives held, partially offset by interest and dividend payments as well as the buy-back of own shares for management options. Core EPS was €0.74 compared to €0.71 for the same period a year ago. The company announced that based on current exchange rates and the 2015 hedge effects, an overall annual positive impact on 2015 EBITDA is estimated at approximately €35 million versus the estimated €45 million indicated in first quarter of 2015, should current rates persist throughout the remainder of the year. DSM aims to deliver an EBITDA in 2015 ahead of 2014, the increase mainly driven by positive foreign exchange effects.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSM:NA €46.27 EUR -0.09

DSM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celanese Corp $65.01 USD -1.83
Eastman Chemical Co $70.82 USD -0.68
Johnson Matthey PLC 2,645 GBp +45.00
Merck KGaA €77.42 EUR -0.83
Solvay SA €101.25 EUR +2.26
View Industry Companies

Industry Analysis


Industry Average

Valuation DSM Industry Range
Price/Earnings 64.3x
Price/Sales 0.9x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at